Antisoma is sending out signals that it's looking for new acquisitions to add to its pipeline. "With a strong balance sheet, we are well placed to invest in and add value to our current pipeline and to add further promising drugs to our portfolio when opportunities arise," Antisoma Chairman Barry Price told The Guardian. The UK biotech has been making significant headway with ASA404, which has been in trials as an anti-cancer therapy. Novartis partnered up on the program last April in a deal valued at around $900 million.
- check out the report in The Guardian